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Abstract
Objective.?–?Steroidogenic?factor?1?(SF-1/NR5A1)?plays?a?crucial?role?in?regulating?adrenal?development,?gonad?determination?and?differentiation,?
and?in?the?hypothalamic-pituitary?control?of?reproduction?and?metabolism.?In?men?(46,?XY),?it?is?known?that?mutations?in?SF-1/NR5A1?gene?cause?
a?wide?phenotypic?spectrum?with?variable?degrees?of?undervirilization.?In?recent?years,?the?role?of?SF-1?in?the?ovarian?function?was?increasingly?
discussed?and?alterations?in?the?gene?were?related?to?primary?ovarian?insufﬁciency.?We?describe?the?follow-up?of?a?46,?XX?affected?woman?with?
a?SF-1?mutation?and?by?comparing?our?case?with?the?known?manifestations?reported?in?the?literature,?we?try?to?further?elucidate?the?function?of?
SF-1?in?the?ovary.?Results.?–?During?infancy,?adrenal?insufﬁciency?was?the?only?clinical?sign?of?the?loss-of-function?as?ovarian?development?and?
function?seemed?normal.?To?date,?this?young?woman?aged?16.5?years?shows?normal?growth,?normal?BMI?and?psychomotor?development,?has?a?
normal?puberty?and?regular?menstruation.?Conclusion.?–?This?report?shows?one,?to?date?uniquely?described,?phenotypic?variant?of?SF-1?mutation?
in?a?46,?XX?affected?person?with?adrenocortical?insufﬁciency?but?no?ovarian?dysfunction?nor?disturbance?of?pubertal?development.?To?follow?the?
natural?history?of?SF-1?mutation?in?a?46,?XX?individual?will?further?shed?light?on?its?role?in?the?ovarian?function?and?thus?will?help?to?counsel?
affected?patients?in?future.
Keywords: Steroidogenic factor 1; Adrenal insufﬁciency; Primary ovarian insufﬁciency; Disorder of sexual development
Résumé
Objectif.?–?Le?facteur?1?stéroïdogénique?(SF-1/NR5A1)?joue?un?rôle?critique?dans?la?régulation?du?développement?des?surrénales,?la?détermination?
et?différentiation?des?gonades?ainsi?que?dans?le?contrôle?hypothalamo-pituitaire?de?la?reproduction?et?du?métabolisme.?Chez?les?hommes?(46,?XY),?
il?est?connu?que?les?mutations?du?gène?SF-1?peuvent?entraîner?de?multiples?phénotypes?avec?différents?degrés?d’impubérisme.?Durant?les?dernières?
années,?l’inﬂuence?de?SF-1?sur?la?fonction?ovarienne?a?été?étudié?et?les?altérations?de?ce?gène?ont?été?mises?en?relation?avec?l’insufﬁsance?ovarienne?
primaire.?Nous?décrivons?le?suivi?d’une?femme?46,?XX?porteuse?d’une?mutation?du?gène?SF-1?et?nous?comparons?notre?cas?clinique?avec?ceux?
de?la?littérature?aﬁn?d’éclaircir?l’inﬂuence?du?gène?SF-1?sur?la?fonction?ovarienne.?Résultats.?–?Durant?l’enfance,?une?insufﬁsance?des?surrénales?
fut?le?seul?signe?clinique?de?cette?mutation,?le?développement?des?ovaires?ainsi?que?leurs?fonctions?semblèrent?alors?normales.?Actuellement?cette?
adolescente?de?16?ans?a?une?croissance,?un?indice?de?masse?corporelle?et?un?développement?psychomoteur?normal,?une?puberté?normale?ainsi?que?des?
menstruations?régulières.?Conclusion.?–?Cette?étude?décrit?une?variante?phénotypique,?d’une?personne?46,?XX,?atteinte?d’une?affection?de?SF-1?avec?
insufﬁsance?surrénale?mais?sans?dysfonctionnement?ovarien?ni?perturbation?de?la?puberté.?Cette?observation?nous?offre?une?opportunité?unique?de?
suivre?l’histoire?naturelle?d’une?mutation?de?SF-1?chez?un?individu?46,?XX?et?peut?contribuer?à?éclaircir?son?rôle?dans?la?fonction?ovarienne,?aﬁn?
de?pouvoir?conseiller?de?futurs?patients.
Mots clés : Facteur 1 stéroïdogénique ; Insufﬁsance surrénale ; Insufﬁsance ovarienne primaire ; Anomalies du développement génital
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1.  Introduction
Human SF-1/NR5A1/AdBP4 [1,2], a member of the nuclear
receptor family (www.nursa.org), is an amino acid protein. Its
crucial functional regions comprise an amino-terminal 2 zinc
ﬁnger DNA-binding domain (DBD), an accessory DNA-binding
region, a hinge region, and a ligand-binding domain (LBD),
which forms an AF-2 structure [3,4].
SF-1/NR5A1 is essential for the regulation of adrenal devel-
opment, gonad determination and differentiation, and in the
hypothalamic-pituitary control of reproduction and metabolism.
It activates key genes and interacts with transcription factors
(DAX1, WT1, SRY, SOX9) involved in sex development. SF-
1/NR5A1 thereby regulates the expression of anti-Müllerian
hormone and the transcription of enzymes of the steroido-
genesis (ACTHR, STAR, CYP11A1, CYP19, CYP17A1) and
testosterone biosynthesis in human males [5]. In both sexes, SF-
1/NR5A1 is expressed in the developing bipotential gonad and
persists later in the testes, namely Leydig and Sertoli cells, as
well as in the ovary [6,7].
However, pathogenic signiﬁcance of SF-1/NR5A1  muta-
tion became clear by analyzing SF-1 mouse-model. Deletion
of the gene (Nr5a1) encoding SF-1 in XY mice resulted in
impaired adrenal development, complete testicular dysgene-
sis with Müllerian structures, and female external genitalia as
well as abnormal structure of the ventromedial hypothalamus,
hyposplenism, hypogonadotropic hypogonadism and late onset
obesity [8–10].
These studies in mice lead to the search for SF-1/NR5A1
mutations in humans displaying primary adrenal failure, 46, XY
gonadal dysgenesis and Müllerian structures. Indeed, in 1999,
Achermann et al. identiﬁed such a mutation in a patient with the
mentioned phenotype [11]. After this discovery, SF-1/NR5A1
mutation related to adrenal insufﬁciency in human 46, XY men
was only reported in one more similar case [12].
In men (46, XY) mutations in SF-1/NR5A1  gene actually
cause a wide phenotypic spectrum of 46, XY disorders of sexual
development (DSD) without adrenal insufﬁciency that ranges
from complete testicular dysgenesis with Müllerian structures
and amenorrhoea, through persons with mild clitoromegaly
or genital ambiguity, to severe penoscrotal hypospadias or
anorchia and oligospermia [5]. To date, SF-1/NR5A1  mutations
are thought to be one of the most common monogenic causes of
46, XY DSD due to gonadal dysgenesis. However, having only
been reported in two individuals with combined 46, XY DSD
and primary adrenal insufﬁciency, its role in the etiology of the
latter seems to be less crucial than initially thought [11–13].
Nevertheless, recently one further case of SF-1  mutation asso-
ciated with primary adrenal insufﬁciency has been reported in a
46, XX female patient harboring a homozygous p.R92Q muta-
tion [14], the same homozygous affection reported in the 46, XY
DSD individual with adrenal insufﬁciency in 2002.
In female mice knockout of SF-1 in granulosa cells results
in hypoplastic ovaries and infertility [15]. In human women
(46, XX), mutations in SF-1/NR5A1  seem to be associated with
impairment of ovarian development and function leading to pri-
mary ovarian insufﬁciency due to low ovarian reserve. Indeed,
SF-1 mutation has been reported in familial and sporadic cases of
primary ovarian insufﬁciency (POI), albeit it is a rather rare cause
in sporadic cases (1.4–8%) [16–18]. However, SF-1 alterations
seem to lead to different degrees of severity of impairment of
ovarian function, depending on the mutation. Therefore, the role
of SF-1 in human ovarian function remains to be more deeply
explored.
2. Materials  and methods
We described the ﬁrst case of a SF-1 insufﬁcient 46, XX
girl in whom, at the age of 14 months, adrenal insufﬁciency
was the only clinical sign of the loss-of-function mutation [19].
Direct sequencing of PCR fragments ampliﬁed from genomic
DNA of the patient revealed the presence of a heterozygote G
to T transversion in exon 4 of the NR5A1  gene, leading to the
missense p.R255L in the hinge region of SF-1/NR5A1 protein.
Functional studies demonstrated that the mutated SF-1/NR5A1
did not bind properly to the known responsive element of the
human CYP11A (cholesterol side-chain cleavage) promoter.
At that time, ovarian development and function seemed nor-
mal on the base of normal ovarian morphology at ultrasound
and MRI (showing an infantile uterus [2.6 cm] and infantile
ovaries of normal size [maximal diameter 1.2 cm] and struc-
ture) and repeatedly normal gonadotropins and ovarian markers
(inhibins). Nevertheless, it remained unknown then whether
this mutation would interfere with ovarian function at onset of
puberty and beyond.
Our follow-up was based on 6-monthly visits at our outpatient
clinic, with measurements of auxological (height and weight)
parameters and evaluation of pubertal development. Hormonal
measurements were performed using commercially available
immunoassays (AMH Gen II ELISA kit by Beckman Coul-
ter; DELFIA hFSH and LH kit by PerkinElmer; ST AIA-PACK
ACTH kit by TOSOH).
3. Results
At the age of ten and a half years, puberty started spon-
taneously with thelarche and pubarche. Finally, at the age of
11 years and 7 months menstruation began spontaneously. At
13.3 years, her bone age was 14.7 years, her height was 153 cm
(P10–25) and her weight 49 kg (P50–75) (Fig. 1). At age 14
and 16.8 years, LH and FSH serum levels were normal for
puberty (LH 14.30 U/L, FSH 6.39 U/L [15th day of menstrual
cycle] and LH 19.7 U/L, FSH 6.25 U/L [14th day of men-
strual cycle], respectively, both times values compatible with
midcycle peak). The marker of ovarian reserve anti-Müller-
Hormone (AMH) showed normal ovarian function with a value
of 17 pmo/L and 36 pmol/L, respectively (NV > 7.1 pmol/L)
(Table 1). Furthermore, ACTH was within normal range
(28 pg/mL and 11 pg/mL). However, at the age of thirteen
years, ACTH level was markedly elevated (> 1250 pg/mL)
due to malcompliance. At age 14, she deliberately lost
weight by changing her eating habits and practicing more
sports.
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Fig. 1. Growth curve.
Table 1
Clinical and biochemical ﬁndings.
Age Bone age Tanner stage ACTH
10–55 pg/mL
LH/FSH (U/L) Day of menstrual cycle AMH
> 7.1 pmol/L
10Y6M B2, P2
11Y 10Y6M B3, P3 0.7/3.2
11Y7M Menarche
11Y10M 12Y6M B4, P4
12Y10M > 1250 6.92/5.45 17
13Y4M 14Y8M
13Y11M 28 14.3/6.4 15 17
16Y9M 11 19.7/6.3 14 36
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Table 2
NR5A1 mutations in 46, XX.
Patient Phenotype Family
member with
46, XY DSD
Mutation rs Frequency
dbGape
Occurence Reference
1 AI No p.R255L 104894118 1/36499 Heterozygous Biason-Lauber et al., 2000 [19]
2 POI Yesa p.N222Kfs 606231206 No data Heterozygous Lourenco et al., 2009 [16]
3 POI Yesb p.D293N 121918655 0/39071 Homozygous Lourenco et al., 2009 [16]
4 POI Yesb p.M1I 121918656 0/37246 Heterozygous Lourenco et al., 2009 [16]
5 POI Yesa p.P131Rfs 606231207 No data Heterozygous Lourenco et al., 2009 [16]
6 POI NM p.L231 L233del 606231208 No data Heterozygous Lourenco et al., 2009 [16]
7 HC NM p.G123A 200163795 46/36999 Heterozygous Lourenco et al., 2009 [16]
p.P129L 200749741 44/35919 Heterozygous
8 No Yesa p.R92Q 104894119 0/37794 Heterozygous Achermann et al., 2002 [12]
9 No Yesb p.R92Q 104894119 0/37794 Heterozygous Achermann et al., 2002 [12]
10 AI NM p.R92Q 104894119 0/37794 Homozygous Guran et al., 2015 [14]
11 Ovotesticular
DSD
No p.R92W 886039769 No data Heterozygous Igarashi et al., 2016 [22]
12 Ovotesticular
DSD
No p.R92W 886039769 No data Heterozygous Igarashi et al., 2016 [22]
13 Ovotesticular
DSD
No p.R92W 886039769 No data Heterozygous Baetens et al., 2016 [23]
14 Ovotesticular
DSD
No p.R92W 886039769 No data Heterozygous Baetens et al., 2016 [23]
15 Testicular
DSD
No p.R92W 886039769 No data Heterozygous Baetens et al., 2016 [23]
16 No Yesa p.R92W 886039769 No data Heterozygous Baetens et al., 2016 [23]
17 No Yesa p.R92W 886039769 No data Heterozygous Baetens et al., 2016 [23]
18 No Yesb p.R92W 886039769 No data Heterozygous Baetens et al., 2016 [23]
19 NM Yesa p.G91S 104894126 0/37721 Heterozygous Lin et al., 2007 [25]
20 NM Yesa p.M78I 104894125 0/32254 Heterozygous Lin et al., 2007 [25]
21 POI No p.A192F No data No data Heterozygous Janse et al., 2012 [17]
22 POI No p.R313H No data No data Heterozygous Janse et al., 2012 [17]
23 POI NM p.R255C No data No data Heterozygous Philibert et al., 2013 [21]
24 POIa NF,
↑FSH
↓AMHb
Yesa,b p.Y183X No data No data Heterozygous Warman et al., 2010 [26]
26 NF, ↑FSH
↓AMH
Yesa p.P179HfsX116 No data No data Heterozygous Coutan et al., 2007 [27]
27 NM Yesa c.1277dupT No data No data Heterozygous Köhler et al., 2008 [28]
28 POI NM p.P235L No data No data Heterozygous Camats et al., 2012 [29]
29 Infertility Yesb p.H24TfsX51 No data No data Heterozygous Camats et al., 2012 [29]
30 EM Yesa p.G90R No data No data Heterozygous Camats et al., 2012 [29]
29 NF, ↑FSH
↓AMHa,c
Yesa,c p.R313H No data No data Heterozygous Ciaccio et al., 2012 [30]
30 POI Yesa 9q33.3 microdel No data No data Heterozygous Harrison et al., 2013 [31]
31 POI No p.Y5D No data No data Heterozygous Jiao et al., 2013 [32]
32 POIa,d
Dep, Anxa
Yesa,d p.D257TfsX39 No data No data Heterozygous Suwanai et al., 2013 [33]
33 Dep Yesa p.V424del No data No data Heterozygous Suwanai et al., 2013 [33]
33 POI Yesa p.C65Y No data No data Heterozygous Fabbri et al., 2014 [34]
AI: adrenal insufﬁciency; POI: Primary ovarian insufﬁciency; HC: hypertrophic clitoris; NM: not mentioned; NF: normal fertility; EM: early menopause; Dep:
depression; Anx: anxiety.
a Mother of patient with 46, XY DSD.
b Sister of patient with 46, XY DSD.
c Mother’s sister of patient with 46, XY DSD.
d Maternal grandmother of patient with 46, XY DSD.
e Potential variants are reported according to dbGaP data (https://www.ncbi.nlm.nih.gov/clinvar/?term=NR5A1%5bgene).
To date at age 16, this young woman shows a normal
growth and psychomotor development, has a normal puberty
with normal breast development (Tanner stage 4) and regular
menstruation. The current treatment of her adrenal insufﬁciency
consists of hydrocortisone (17.4 mg/m2/day) and ﬂudrocorti-
sone (0.05 mg/day).
4.  Discussion
Over the last years, mutations in SF-1/NR5A1  were shown to
lead to different kind of phenotypes in 46, XX and XY affected
individuals. The adrenals as well as the hypothalamo-pituitary-
gonadal axes can be affected leading to several heterogeneous
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clinical presentations. In fact, SF-1 is involved in regulat-
ing adrenal development, gonad determination/differentiation,
and in the hypothalamic-pituitary control of reproduction and
metabolism. Heterozygote mutations in SF-1 are one of the most
common causes of 46, XY disorders/differences of sex devel-
opment (DSD) due to gonadal dysgenesis. The role of SF-1
mutations in adrenal and ovarian physiology is less clear.
Our patient was the ﬁrst described affected 46, XX female
patient with an SF-1/NR5A1  loss of function mutation leading
to adrenal insufﬁciency [19]. Adrenal insufﬁciency seems to be
rare in SF-1 insufﬁciency. Although the ﬁrst described patient
was adrenal insufﬁcient [11], since then only few more patients
with adrenal insufﬁciency and SF-1 mutations were identiﬁed,
including ours. The ﬁrst alteration found was a de novo p.G35E
heterozygous dominant mutation in the P-box primary DNA-
binding region, the second was a recessively inherited p.R92Q
homozygous frameshift mutation in the A-box secondary DNA-
binding region [12]. Recently, the same homozygous p.R92Q
mutation was found in a 46, XX girl with early onset primary
adrenal insufﬁciency [14]. The G to T transversion in exon 4
in our patient is predicted to be deleterious by Alamut Software
alamut.interactive-biosoftware.com (comprehending the predic-
tion programs PolyPhen-2, SIFT, Mutation taster, AlignGVGD
and KD4v) and reported to be pathogenic. Even more rele-
vant than predictions, our published data [19] demonstrated that
the mutation lead to a loss of transactivation potential of the
mutant SF-1. The fact that this heterozygous p.R255L variant
was later found in 2/15056 South Asians (rs104894118) without
any apparent disease, is most likely due to different penetrance
of the mutation or modifying inﬂuences of other genes related
to other genetic background in different populations.
In women, SF-1  mutations have been related to POI, due
to decreased expression of steroidogenic enzymes and compro-
mised granulosa cell proliferation leading to impaired follicle
development [20]. Mutations can be found in about 1.4–1.6%
of women presenting with sporadic POI of unknown origin
[16–18,21], with alterations of SF-1 including the hinge region,
similarly to our patient.
In women, there is also a wide phenotypic spectrum of clinical
impact from no apparent consequence to early primary ovarian
insufﬁciency [16] (Table 2). Recently, in 46, XX individuals a
heterozygous p.R92W mutation was found in association with
several cases of ovotesticular DSD [22,23]. The fact that the
same mutation can lead to different clinical pictures even in the
same family suggests various degrees of penetrance due to co-
modulating and/or epigenetic factors inﬂuencing SF-1 activity
and integrity [16,21–24].
Our patient showed that despite impaired SF-1 integrity the
ovaries are macroscopically normal and show a normal func-
tion before and after birth, throughout and beyond puberty. We
suggest accordingly to previous data in humans [16] that SF-1
integrity is not essential for normal fetal ovarian development
and early function, although it may play an important role in
maintaining ovarian integrity. Careful clinical follow-up of this
unique case will help to evaluate this hypothesis in an in vivo
human clinical setting. Furthermore, it may help to predict the
clinical course of similar cases and therefore better counsel and
monitor future patients for potential risk of adrenal or gonadal
insufﬁciency.
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